July 31, 2019 — Silicon Valley-based digital health company Eko announced Eko Home, a new service that enables precise remote monitoring of cardiac function using electrocardiogram (ECG) and heart sounds. Eko Home can be used to create drug-data combinations to demonstrate real-world efficacy for pharma trials, while simultaneously allowing clinicians to collect high-quality data while outside of the clinical environment.
The Eko Home application is currently being used in an active Mayo Clinic study. The purpose of the study is to evaluate different strategies of cardiovascular therapy with carvedilol, aiming to reduce the incidence of heart function declines and heart failure in at-risk breast cancer patients while on trastuzumab therapy.
The future of drug trials includes better data and continuous monitoring, according to a recent Harvard Business Review article. Per the authors, digital technologies “can revolutionize the antiquated process of developing new drug therapies and can vastly improve how we collect, measure and assess health data so that we can offer new treatments to patients without wasting valuable time and limited resources.” This is exactly what Eko Home offers to researchers, according to the company, providing precise monitoring for home cardiac patients using ECG and heart sounds, as well as other biometric data.
Eko expects to offer the drug-data combinations with other life science partners by the end of the year, with additional plans to offer its SDK to hospitals and healthcare providers that wish to build the platform directly into their applications.
For more information: www.ekohealth.com
August 15, 2024 
